Feedback / Questions
atebimetinib (IMM-1-104) - Immuneering
https://www.globenewswire.com/news-release/2025/09/24/3155829/0/en/Immuneering-Announces-Extraordinary-86-Overall-Survival-at-9-Months-in-First-Line-Pancreatic-Cancer-Patients-Treated-with-Atebimetinib-mGnP.html
Sep 24, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next